Colin Rom is a partner and the Head of Public Policy for Bio+Health at Andreessen Horowitz.

Prior to joining a16z, Colin was the Managing Director of Science and Innovation Policy at Mayo Clinic, leading federal engagement strategy and policy creation in areas including artificial intelligence, emerging biotechnology, and care delivery modernization. Before Mayo, Colin spent two years as a senior advisor to the Commissioner of Food and Drugs at the U.S. Food and Drug Administration (FDA), leading several agency-wide initiatives and serving as a liaison between the FDA and White House Coronavirus Task Force during the first year of federal COVID-19 response. He also spent one year at the White House Office of Management and Budget as a policy and political advisor to the Health Program Associate Director and five years as a health policy advisor in the United States Senate, working for Senator Richard Burr (N.C.) and the Senate Committee on Health, Education, Labor, and Pensions.

Colin graduated from the University of Mary Washington and is completing an M.S. in Biotechnology Enterprise and Entrepreneurship from Johns Hopkins University.